As shown in Fig. 4, peptide R-treated gliomas showed a reduction of CD11b+ and CD68+ cells migrated at the tumor edge (Fig. 4a and b) as compared with control and Plerixafor groups. Here, ITGAM is linked to central nervous system cancer.